GlassScriptPhysician profile
Marwan A Odeesh
NPI 1568803054
$12,322.21
in general payments reported to CMS, 2019-2025
29 companies · $787 in 2025
The $787 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.11 · 2020: $13.14 · 2021: $217 · 2022: $259 · 2023: $11K · 2024: $448 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,000 · Food and Beverage: $1,889 · Travel and Lodging: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.00 |
| Food and Beverage | $1,888.84 |
| Travel and Lodging | $884.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,014.60 | 2023-2025 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $455.26 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $345.81 | 2021-2025 | Tezspire, Fasenra, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.77 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $172.05 | 2024-2025 | Image Management Subscription, Vest Therapy Und, (Ae4) Secretion Management |
| Electromed, INC. | $130.43 | 2023-2025 | Smartvest |
| Galvanize Therapeutics, INC | $127.46 | 2025 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $104.71 | 2023-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $91.49 | 2021-2023 | Opsumit, Uptravi |
| Amgen INC. | $77.62 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $72.72 | 2019-2023 | Yupelri |
| Baxter Healthcare | $66.29 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $46.27 | 2022-2024 | |
| United Therapeutics Corporation | $42.96 | 2023-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $40.36 | 2023 | Glassia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $39.53 | 2021-2023 | Fetroja |
| Vapotherm INC | $36.25 | 2022 | |
| Insmed, INC. | $34.84 | 2021-2022 | |
| Verona Pharma, INC. | $33.16 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $23.75 | 2023 | |
| Edwards Lifesciences Corporation | $22.13 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.90 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $21.27 | 2023 | Cresemba |
| Jazz Pharmaceuticals INC. | $20.30 | 2021 | |
| Inspire Medical Systems, INC. | $20.05 | 2025 | Inspire |
| Grifols USA, LLC | $18.80 | 2025 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $17.28 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.55 | 2019 | |
| Ambu INC. | $11.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Odeesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.